兰州大学学报（医学版）2023，Vol.49Issue(10)：52-59,72,9.DOI:10.13885/j.issn.1000-2812.2023.10.008
新辅助免疫治疗联合化疗治疗局部晚期可切除食管鳞状细胞癌的短期疗效观察
Short-term efficacy of neoadjuvant immunotherapy combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma
摘要
Abstract
Objective To evaluate the safety,efficacy and clincal short-term outcomes of neoadjuvant immu-nochemotherapy(nICT)in the treatment of patients with locally advanced resectable esophageal squamous cell carcinoma(ESCC).Methods A retrospective analysis was performed to consecutive patients(from June 2020 to May 2023)who underwent Mckeown esophagectomy for locally advanced resectable ESCC with or without nICT.According to the different treatments,the patients were divided into two groups:the nICT group and the surgery alone group.The baseline characteristics,perioperative indicators and incidence of post-operative complications were compared between the two.To evaluate the efficacy of nICT,objective response rate(ORR),postoperative pathological response rate and incidence of adverse events during the nICT were analyzed.Results A total of 195 patients were included in the study,with 59 in the nICT group and 136 in the surgery alone group.The baseline data of the two groups were comparable.Compared with the surgery alone group(303.3±69.7)min,operation time was significantly longer in the nICT group(357.7±89.9)min(P<0.001).However,there was no significant difference(P>0.05)between the two groups in the R0 resec-tion rate,intraoperative blood loss,number of dissected lymph nodes,postoperative complications,chest tube duration,postoperative hospital stay and 60-day mortality rate.In the nICT group,the ORR was 64.4％,patho-logical complete response rate 28.8％and the major pathological response rate 39.0％.The incidence of grade 3 treatment-related adverse events was 20.3％,and there were no≥grade 4 adverse events during the neoadju-vant therapy.Conclusion NICT followed by Mckeown esophagectomy for locally advanced ESCC did not increase postoperative complications,and adverse events were controllable.It was a safe and feasible neo-adjuvant treatment model while further multicenter prospective trials are needed to validate our results.关键词
食管鳞状细胞癌/新辅助免疫化疗/信迪利单抗/食管切除术/术后并发症Key words
esophageal squamous cell carcinoma/neoadjuvant immunochemotherapy/sintilimab/esophagec-tomy/postoperative complications分类
医药卫生引用本文复制引用
陈玉珍,任美玉,李斌,王成,蒋鹏,孟于琪,冯海明,蔺军平,余琦瑶..新辅助免疫治疗联合化疗治疗局部晚期可切除食管鳞状细胞癌的短期疗效观察[J].兰州大学学报（医学版）,2023,49(10):52-59,72,9.基金项目
甘肃省重点人才资助项目(2021RCXM062) （2021RCXM062）
吴阶平医学基金临床研究专项基金资助项目(320.6750.2021-23-12) （320.6750.2021-23-12）
